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Introduction 
The misuse of drugs in prison is one of the biggest challenges facing our criminal justice 
system today. Drug misuse is prevalent and contributes to violence, crime and 
vulnerability within prisons, which threatens safety and the ability of our hard-working 
prison staff to deliver effective regimes. We will not be able to improve safety, prevent 
reoffending and tackle serious and organised crime without reducing the misuse of drugs 
in prisons. This is a complex, multi-faceted problem with no simple answer – it requires a 
coordinated effort to limit the supply of drugs both inside and outside prisons, encourage 
people away from drug misuse towards positive and productive activities, and support 
those requiring treatment. It is therefore crucial that our approach to tackling the problem 
considers the whole system, working across government and with our partners at a 
national, regional and local level.  
The scale of the problem is significant and has become more challenging in recent years. 
Between 2012/13 and 2017/18, the rate of positive random tests for ‘traditional’ drugs1 in 
prisons increased by 50%, from 7% to 10.6%, and drug use in prisons is now widespread, 
particularly in male local and category C prisons. The emergence of psychoactive 
substances such as synthetic cannabinoids has exacerbated the problem, and these are 
often used in conjunction with other drugs, while we remain aware of problems with the 
diversion and misuse of prescription medication. The prevalence and patterns of drug 
misuse in prisons is shaped by patterns in the community, and the challenges faced by 
prisons can be exacerbated when those entering prison have an existing drug misuse 
issue or when drug misuse has been normalised in the community. 
Evidence shows us that the prisons with the highest rates of positive random drug tests 
are the prisons that are the least stable.2 The misuse of drugs contributes to a cycle of 
disruption and violence, leading to a reduced or unstable regime, which through 
unpredictability and lack of purpose can encourage prisoners to turn to drugs and alcohol. 
The debt resulting from the supply, distribution and use of drugs is also a significant cause 
of violence, intimidation and self-harm across the estate, endangering both staff and other 
prisoners. Consequently, to tackle drug misuse, we need changes in all elements of this 
cycle, enabling prisoners to engage positively with rehabilitation, in a calm and safe 
environment. Reducing drug misuse is crucial to the safety of our prisons and the 
rehabilitation of prisoners. 
This strategy has been developed by the Ministry of Justice (MoJ) and Her Majesty’s 
Prison and Probation Service (HMPPS), working with other partners across government. It 
sets out our plans to reduce the misuse of drugs in our prisons, and will provide direction 
to assist all stakeholders in this. We are also releasing detailed guidance for prisons to 
support them in identifying issues and share best practice. Together, we will focus on 
                                               
1 Rates of positive drug tests are split between ‘traditional’ drugs – controlled substances defined in 
the Misuse of Drugs Act 1971, such as opiates and cannabis – and ‘psychoactive substances’ – 
substances initially defined in the Psychoactive Substances Act 2016, such as synthetic 
cannabinoids, but many of which have now been controlled by the Misuse of Drugs Act 1971. 
2 Ministry of Justice, (2016), Prison Safety and Reform White Paper, 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/fil
e/565014/cm-9350-prison-safety-and-reform-_web_.pdf, p. 41. 
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restricting the supply of drugs by improving security, building intelligence, and targeting 
the criminal networks which aim to bring drugs into prison. We will also reduce the 
demand for drugs in prison by developing more meaningful regimes, providing more 
constructive ways for prisoners to spend their time and ensuring the balance of incentives 
encourages prisoners to make the right choices. We will work closely with our health and 
justice partners to build recovery for prisoners who want to overcome their substance 
misuse, providing prisoners who are serious about living substance free with the 
environment to do so successfully. It is crucial that we deliver all three strands of this 
strategy in unison to make a meaningful, positive difference to both prisoners and staff. 
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Delivering this strategy 
Our aim 
This strategy has been developed to support and complement the HM Government Drug 
Strategy developed by the Home Office in 20173 and is centred around the same three 
objectives of restricting supply, reducing demand and building recovery. Our overall aim is 
to reduce drug misuse in our prisons, which will increase safety for both staff and 
prisoners, and contribute towards ensuring that prisons are places of opportunity and 
change for prisoners. Our priorities are to reduce activities that cause serious harm, 
enable prisoners to live law-abiding lives, and support them to overcome addiction. This 
requires commitment at a national, regional and local level and so all prisons will have 
implemented their own Drugs Strategy, tailored to their specific needs and challenges, by 
September 2019. 
Our approach 
To tackle the problem of drug misuse in prisons, we need to prevent drugs being available 
in prisons (restrict supply), support prisoners to reduce and avoid drug misuse (reduce 
demand), and provide the help and treatment they need to maintain their recovery 
(building recovery). To achieve these objectives, we are focusing on five areas that impact 
the levels of drug misuse in prisons. 
People – that prisons have the right staff, with appropriate skills and support 
Procedural – that prison processes are clear, fair and effective 
Physical – that prison conditions are safe, clean, decent and promote well-being and 
recovery 
Population – that prisoners have positive relationships and engage in constructive 
activities 
Partnership – that all the organisations contributing to achieving our aims work together 
effectively 
For each of the three objectives, we have identified key activities in each of these five 
areas as well as aims against which we can measure our progress. These include central 
activities, such as developing intelligence, and local initiatives, such as working well with 
community-based treatment providers. 
Alongside this strategy, we have developed a catalogue of good practice and guidance for 
prison governors and staff to consider when managing the day-to-day running of their 
prison to minimise drug misuse. We will continue to work with prisons to share and 
                                               
3 Home Office, (2017), 2017 Drug Strategy, https://assets.publishing.service.gov.uk/government/ 
uploads/system/uploads/attachment_data/file/628148/Drug_strategy_2017.PDF 
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implement changes which have proven to be successful and update the guidance. This 
will support prisons in developing their local drugs strategies in conjunction with other 
activity, including local safety strategies. We will guide and support prisons to make 
improvements that lead to real and positive change across the prison estate. 
Closed male prisons have particularly challenging issues with substance misuse. 
Consequently, some parts of this strategy and the accompanying guidance have a 
particular focus on these prisons. However, the key principles and much of the best 
practice are equally applicable across the estate, and where we learn lessons in closed 
male prisons, we can then share effective approaches. We are also targeting specific 
investment in challenging areas to test our approach. We are concentrating additional 
effort on ten prisons with significant challenges. These 10 prisons are benefitting from an 
initial £10 million of additional investment, £6 million of which was specifically allocated to 
tackling drugs. We are working closely with regional and local colleagues through a Drug 
Diagnostic process to identify the specific challenges in each prison and recommend 
actions to combat these. We are providing all of the ten prisons with body scanners, drug 
detection dogs, additional staff and security equipment as well as specific investment 
where local needs are identified. 
In addition, our £9 million joint MoJ/HMPPS, NHS England and DHSC (Department of 
Health and Social Care) Drug Recovery Prison pilot is testing and evaluating innovative 
approaches to tackle drugs in prison and help prisoners to improve their chances of 
recovery. This focused investment will give us the best opportunity to make these prisons 
the best that they can be, provide consistency in delivery and inform our understanding of 
what works best for the rest of the prison estate. We will use what we learn from the work 
in the ten prisons and the Drug Recovery Prison pilot to develop evidence-based 
approaches that inform our work across all prisons. 
All of the relevant organisations working together is key to ensuring that we respond 
effectively. To do this, we have established a cross-government steering group which 
brings together health, justice and law enforcement organisations to combine their 
influence and benefit from their expertise and experience in shaping how to tackle the 
misuse of drugs in prisons. We are also working closely with front-line prison staff to 
ensure that our approach works well in practice. 
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To reduce drug misuse in prisons, we will 
Restrict supply Reduce demand Build recovery 
• Minimise the supply of drugs 
into prisons through 
guidance, processes and 
technology. 
• Find drugs that do enter 
prisons using searching, 
intelligence and drug testing. 
• Disrupt the trade of drugs 
within prisons, working with 
law enforcement, sharing 
information and tackling 
corruption. 
• Ensure there are the right 
incentives in prisons to 
encourage and support 
prisoners to make good 
decisions. 
• Provide productive 
opportunities and 
constructive relationships 
with staff to steer prisoners 
away from drugs. 
• Engage with families, friends 
and peers to help prisoners 
develop networks that will 
support them to avoid 
substance misuse. 
• Collaborate with health 
partners to ensure successful 
commissioning and delivery 
of substance misuse 
services. 
• Share successful initiatives 
from the Drug Recovery 
Prison pilot to build a whole 
prison, recovery focus. 
• Work with community 
partners to ensure that 
prisoners receive continuity of 
care when released from 
prison. 
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Issue 
The availability of drugs in our prisons is a threat to safety and security, obstructing 
recovery for prisoners with drug misuse issues and leading others to develop issues while 
in prison. Drugs enter prison in a variety of ways, including coming through the front gate, 
being thrown over the perimeter, through visits and post, and deliveries by drones. Many 
Prison Drugs Strategy 
9 
instances are arranged using illicit mobile phones, particularly as phones have become 
smaller and harder to detect using traditional scanning tools. To tackle this, we are 
continually improving all of the barriers to drug supply, including technology, processes 
and physical defences to minimise the opportunities for drugs to be conveyed. Often drug 
smuggling into prisons forms part of a complex illicit economy, driven in part by 
sophisticated and organised criminals. Therefore, identifying and disrupting those at the 
centre of this organised crime is crucial, as well finding any drugs that do enter our 
prisons. 
Drug testing helps us to understand the prevalence of drugs in the prison estate. The 
percentage of positive results from random Mandatory Drugs Tests (rMDT) showed a 
steady rise in the three most recent financial years and in 2017/18, 20.4% of rMDT in 
England and Wales were positive. This includes the results of tests for psychoactive 
substances, which were published for the first time in 2018. Excluding tests for 
psychoactive substances from the data, the rate of positive rMDT in 2017/18 was 10.6%, 
up from 9.3% the previous year. The spread of psychoactive substances has been 
significant, with psychoactive substances present in 60% of all positive samples in 
2017/18.  
In 2017/18 the number of incidents where drugs were found in prisons increased to 
13,119. This was up from 10,666 in the previous year, an increase of 23%. Psychoactive 
substances were found in 4,667 incidents in 2017/18. The volume of drugs recovered 
reflects not only the number of attempts to convey illicit substances into our prisons but 
also our success in finding and recovering these drugs. We are continuing to work to 
enable all prisons to minimise drug supply, find contraband and disrupt illicit trade within 
prisons. 
Our Work 
Minimise the supply of drugs 
Minimising the supply of drugs into prisons – whether through the gate or over the 
perimeter - is the first step in reducing their prevalence and we already have a range of 
techniques to minimise supply. For example, we use body searches, metal-detecting 
scanners and drug detection dogs across the estate, and in closed prisons, visitors and 
arriving prisoners are searched before entering. Strengthening staff resilience to 
corruption, combined with identifying and prosecuting those who abuse their position for 
personal gain, is also key to this. 
To strengthen gate and perimeter security, we will be extending the use of x-ray scanners 
more widely across the estate to detect internally concealed contraband and are also 
investing in more and newer cutting-edge mobile phone denying technology to prevent 
prisoners organising drug supply and trade. These investments will total £6 million. We 
are also developing specific gate and perimeter security approaches in response to new 
threats, such as the emergence of psychoactive substances (PS). We have trained an 
additional 300 drug detection dogs specifically to detect psychoactive substances and are 
also committed to developing methods to identify and pursue the criminal networks 
supplying these substances. This requires investment in trace detection equipment to 
identify items, such as clothing and letters, which have come into contact with 
psychoactive substances.  
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We will be developing improved minimum security standards for all prisons across the 
estate. As part of this, our ambition is to extend the use of enhanced gate and perimeter 
security, similar to that found in an airport, particularly in local prisons that face some of 
the greatest challenges with substance misuse. This includes greater searching and 
scanning technology, such as x-ray scanners for bags and personal items, trace detection 
scanners and metal detecting arches and wands.  
Minimising the supply of drugs is not only about technology. It is also important that we 
maintain effective processes and respond to new methods for smuggling drugs. We have 
established a dedicated Security Risk Unit, which identifies new and emerging threats and 
ensures that prisons are prepared for these, with up-to-date information and technology. 
The use of paper impregnated with psychoactive substances has shown that criminals 
continue to innovate and we must respond. We have provided guidance on how to detect 
and respond to attempts to convey drug-laced paper to all prisons and this will assist 
prisons in their efforts to tackle this supply route. We have also worked to consolidate 
guidance for staff to review and improve their visits processes to reduce the opportunity 
for people to bring in and convey illicit substances. The guidance will also assist staff in 
strengthening prison reception practices to identify prisoners who are suspected of 
smuggling drugs into prisons on entry. This will include a focus on those who may 
intentionally breach their licence conditions in order to bring drugs back into prison, either 
for profit or under duress. 
Every prison is different, and will benefit from tools to assess their specific security needs. 
We have worked with prisons to carry out Vulnerability Assessments in prisons to build a 
picture of the security risks and enable establishments to better target their resources to 
tackle them. This resource will continue to be offered across the estate. The Drug 
Diagnostic toolkit used for the prisons in the 10 Prisons Project has also proved to be 
useful in identifying key issues in different establishments and so we will share this for use 
across the whole estate, supporting prisons to identify where changes could have the 
greatest impact.  
Find contraband 
Together with minimising the supply of drugs, we must ensure that drugs and other 
contraband that do get into prisons are found and removed. Finding contraband relies on 
our dedicated staff having time to search and take follow-up action. We have already 
recruited over 4,700 new staff and are continuing to recruit as well as ensuring that all 
staff are provided with necessary, relevant and useful training. We will also be rolling out 
specialist search teams across the estate, acting on intelligence to prevent and deter 
criminal activity and find contraband. We have also invested in nearly 6,000 body-worn 
video cameras for prison officers as a visible deterrent against violence and crime. 
Finding drugs and identifying those with drug misuse problems is further supported by an 
effective drug testing regime. Prisoners who test positive can be subject to sanctions, as 
well as being supported to access treatment, and so testing is key to encourage prisoners 
to remain drug free and help them to maintain this. The testing process also helps to 
monitor trends in drug use in prison, inform activities that reduce the prevalence of drugs 
in prisons, and contribute to intelligence about the supply and use of drugs. The results of 
testing contribute towards drug treatment policies and enable governors and healthcare 
providers to better understand the needs of their prisoners. 
Prisons use a variety of drug testing approaches. Prisoners can be required to undertake 
monthly random Mandatory Drug Testing (rMDT) or Suspicion-Based Drug Testing, or can 
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volunteer for Compact-Based Drug Testing to demonstrate that they are free of drugs, 
while clinical testing can be used for healthcare purposes. In September 2016, we 
became the first prison service in the world to introduce innovative mandatory drug tests 
for psychoactive substances, which is a significant step in tackling the supply and use of 
them. 
Work is currently underway to introduce more innovative approaches to drug testing to 
improve its effectiveness. We are moving to a more comprehensive approach by 
enhancing rMDT, ensuring that we test for all relevant substances and cracking down on 
the misuse of pharmacy and prescription medicines. This will provide us with better 
information to support our work, enabling us to spot trends and react quickly to changes. 
Disrupt illicit trade 
Our staff and technology are supported by our knowledge of those responsible for drug 
smuggling in prisons and their methods. Disrupting illicit trade and criminal networks 
inside prisons prevents and deters the supply of drugs and contraband. Some of the most 
prolific offenders are difficult to detect, as they use various tactics to hide their activities, 
including exploiting other offenders to hold contraband for them, and so our use of 
intelligence is key. 
HMPPS National Intelligence Unit is working with prisons, probation and law enforcement 
partners to pro-actively develop intelligence on offenders who present the greatest threat 
to prison security and public protection, including those involved in the supply of drugs. 
They focus on supporting successful investigations and prosecutions where there is 
ongoing criminality, as well as building a culture of joint working and information sharing 
with law enforcement to make prisons and our communities safer. We have invested a 
further £3 million to establish the Serious Organised Crime Unit, made up of national and 
regional teams that will relentlessly undermine and disrupt serious and organised crime by 
providing support to local prisons and probation teams, and working closely with law 
enforcement.  
With the support of these specialist units, prisons will be better equipped to work closely 
with law enforcement agencies and other local service providers to build and share 
intelligence on criminal networks, in line with commitments in the Serious and Organised 
Crime Strategy4. Targeted joint action has and will lead to significant convictions and 
improvements in security measures, severely restricting criminals’ ability to supply drugs 
into prisons.  
To make best use of our intelligence, we are investing £1 million in a national digital 
categorisation service, which will provide a wider range of information on male offenders 
coming into prison, including those who may have the means to smuggle drugs, to support 
decisions about where they are placed and how the security risks they pose are managed. 
We have also recently established a specialist financial crime unit to identify and freeze 
bank accounts linked to organised crime in prison, money laundering and drug dealing. 
This will hinder the activity of criminal networks and those who supply drugs in prison. 
                                               
4 HM Government, (2018), Serious and Organised Crime Strategy, 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/fil
e/752850/SOC-2018-web.pdf 
Prison Drugs Strategy 
12 
The guidance provided to prisons alongside this strategy will also help governors to 
disrupt illicit trade and supply within their establishments from other sources. This includes 
working with healthcare providers to ensure prescribed medicines are provided in a safe 
and secure manner, and identifying and prosecuting those guilty of corruption. We are 
launching a revised structure for the Counter Corruption Unit in 2019 which will improve 
the use of intelligence to tackle corruption, including drug trafficking. In addition to this, a 
new Counter Corruption Policy Framework is being developed to strengthen resilience 
against staff corruption in prisons and support prisons and law enforcement in identifying 
staff who use their position for illicit gain. 
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Our Aims  
To reduce the proportion of random Mandatory Drug Tests (rMDT) that are found to be 
positive by March 2020. 
We Will 
• Provide guidance and advice to all prisons on security measures 
including searching, prison reception, visits and new methods by 
People April 2019.  
• Share the Drug Diagnostic toolkit with all prisons by April 2019, 
alongside guidance to assist each prison in identifying improvements 
in their practice.  
• Review our approach to drug testing to ensure it is comprehensive 
Procedural and balanced. 
• Launch a restructured Counter Corruption Unit to tackle corruption, 
including drug trafficking, by spring 2019. 
 
• Extend the use of enhanced gate and perimeter security across the 
Physical prison estate, particularly in local prisons. 
• Increase the searching of all entrants to prisons, including prisoners, 
visitors and staff. 
Population 
• Develop the Digital Categorisation Service to provide a wider range 
of information on male offenders coming into prison, including those 
who may have the means to smuggle drugs into prison. 
• Build our national and regional intelligence units to develop 
intelligence on those offenders who pose the greatest threat to prison 
Partnerships 
security.  
• Work with law enforcement to implement the commitments in the 
Serious and Organised Crime Strategy for lifetime offender 
management of priority organised criminals in prison, to prevent and 
disrupt their offending. 
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Reducing Demand 
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Issue 
While there is demand for drugs in prisons, criminals will seek to exploit that demand. 
Consequently, if demand is not reduced, then restricting drug supply as set out above, 
would lead to increased prices and potential profits for those criminals seeking to supply 
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drugs. Therefore, our Drugs Strategy will tackle the demand for drugs alongside restricting 
the supply of them, as it is only by reducing the market for drugs that we will be able to 
reduce their prevalence. Reducing the demand for drugs relies upon ensuring that 
prisoners understand the consequences of drug use, both within the prison and the wider 
risks to themselves and their families, and offering opportunities that give purpose and 
direction. 
Her Majesty’s Inspectorate of Prisons’ 2017/18 prisoner surveys stated that 13% of adult 
male prisoners said they had developed a problem with illicit drugs in their current prison, 
while 11% said they had developed a problem abusing medication not prescribed to 
them.5 It also showed that 42% of female prisoners and 28% of male prisoners reported 
that they had had a drug problem (including with illicit drugs or with medication not 
prescribed to them) when they arrived in their current prison.6 Prisons should be places of 
positive change and recovery and so we must support prisoners to avoid drug misuse. 
Our Work 
Incentives 
Everything that happens in a prison influences the behaviour and actions of the prisoners 
that it holds. Misuse of drugs can result in prisoners getting into debt, involved in violence 
and other crime or being exploited by other prisoners. We are working to tackle these issues 
holistically and ensure that prisoners understand the risks of their actions and so local 
prison drugs strategies will be closely linked to safety strategies and other initiatives. Many 
prisoners with drug misuse issues also have mental health conditions and so our approach 
involves healthcare, safety and support, as well as restricting supply. To reduce demand 
for drugs in prisons we need to ensure that the incentives guide people towards making 
positive choices that lead them away from drugs and towards opportunities for recovery. 
To do this, we have learnt from previous work on drug recovery wings to develop the 
Identified Substance User (ISU) and Incentivised Substance Free Living (ISFL) concepts. 
Our ISU approach will help prisons to respond effectively when an individual fails a drug 
test by offering support and treatment to those who want to abstain and clear guidance 
about sanctions for repeat offenders who will not engage with support. This will be further 
boosted by a review of the adjudications process and our plans to create a single 
evidenced-based policy framework, encompassing both the adjudications process and the 
crimes in prison protocol. ISFL wings will allow prisoners who demonstrate, through 
regular voluntary testing, that they are not misusing drugs to experience better living 
conditions. This is about giving prisoners the opportunity to take responsibility for their 
own recovery, or insulate themselves from the risks of becoming involved with drugs, and 
helping them to persevere with that choice. 
We have consulted prison governors and stakeholders on a new Incentives and Earned 
Privileges policy framework, which has been developed to empower prisons to use 
sanctions and rewards to support and encourage prisoners to engage with productive 
activities and treatment. This will help us to create environments built on mutual respect 
                                               
5 HM Chief Inspector of Prisons for England and Wales, (2018), Annual Report 2017-18, 
https://www.justiceinspectorates.gov.uk/hmiprisons/wp-content/uploads/sites/4/2018/07/ 
6.4472_HMI-Prisons_AR-2017-18_Content_A4_Final_WEB.pdf, p.26. 
6 Ibid., p.126. 
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and trust, where prisoners know what is expected of them and what they can expect in 
return. In the short term, it will encourage prisoners to engage in activities including 
education, work and treatment, taking responsibility for their own wellbeing, which in turn 
will support them in making better choices about drugs. And in the longer term, these 
changes will place a far greater emphasis on the role that learning and employment have 
to play in rehabilitation and risk reduction.  
Opportunities 
A 2016 study found that many prisoners feel that using drugs will help relieve boredom 
and provide temporary respite from depression and anxiety7. Consequently, ensuring that 
the prison environment provides opportunities to engage in purposeful activity and commit 
to positive change is key to providing hope for the future and encouraging prisoners to 
turn away from drugs. Our Education and Employment Strategy will support prisoners on 
a path to employment from the moment they enter prison, and we will use Release on 
Temporary Licence to support prisoners to get back into work. The New Futures Network 
brokers partnerships between prisons and employers to create opportunities for ex-
prisoners on release, as well as delivering purposeful activity in prison. We are also giving 
prison governors more freedom over how they use their education budget so that they can 
provide their prisoners with the skills that they will need on release from prison. This will 
help to ensure that prisoners are out of their cells as often as possible, with productive 
activities, while in-cell activities will help to ensure prisoners are positively engaged when 
in their cells too. 
Hard-working and dedicated staff underpin all our work. Additional prison officers have 
been recruited to deliver key work and will also help to ensure that prisons have the staff 
that they need to operate more structured and reliable regimes. With the roll-out of the first 
phase of the new Offender Management in Custody model, prison officers will be 
undertaking a keyworker role where they will each work closely with a small number of 
prisoners. This will allow them to build constructive relationships to support prisoners to 
feel safe, calm and settled with the aim of improving safety. Phase Two of the OMIC 
model will introduce a new approach to offender management with a clearer focus on 
planning sentences and supporting prisoners so that staff understand better individual 
needs and risks. This will include guiding prisoners towards treatment and support that 
could help them with substance misuse problems, and engaging them in meaningful 
activity which steers them away from drugs. We have started a process to review our 
existing substance misuse and mental health training offer to ensure our staff receive 
robust and effective training in these areas. 
Families and peers 
Finally, there are other key individuals in the lives of prisoners who help to shape their 
thinking and decision-making. Lord Farmer’s review of the importance of prisoners’ family 
ties highlighted links between family relationships and the use of illicit drugs, and we are 
taking forward the recommendations of that review8. The role of families and fellow 
prisoners in helping people to make and commit to good decisions is vital, and we are 
                                               
7 User Voice, (2016), Spice: The Bird Killer, What prisoners think about the use of spice and other 
legal highs in prison, 
https://drive.google.com/file/d/0BzKDGOPNOkMDVmVhYlVxN2VnS3c/view, p.3. 
8 Lord Farmer, (2017), The Importance of Strengthening Prisoners’ Family Ties to Prevent 
Reoffending and Reduce Intergenerational Crime, https://assets.publishing.service.gov.uk/ 
government/uploads/system/uploads/attachment_data/file/642244/farmer-review-report.pdf 
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working to ensure that prisons make good use of positive influences. Drug misuse can 
also affect families and friends, as they try to support prisoners and can find themselves 
under pressure to get into debt or convey drugs into prisons. Backed with education and 
awareness campaigns to help prisoners to make good decisions, including careful 
guidance about the risks of emerging harmful substances, prisons will be able to draw on 
a range of resources to support their prisoners. 
Evidence suggests there are clear benefits of having a good peer support model within a 
secure setting, including increased positive self-identity, employability skills for the peer 
worker and a positive impact on the attitudes, engagement and behaviour of the 
recipients.9 We published a new peer support toolkit in May 2018 which is supporting and 
facilitating the development of peer support across the prison estate. Prisons also have an 
important role in insulating prisoners from negative influences and so the selection of peer 
supporters must be carefully considered to ensure that the position cannot be abused. 
Prisoner representatives can also perform an important role in communicating between 
prisoners and staff about issues of concern, security, safety and decency. 
 
                                               
Our Aims  
To progressively increase the time that prisoners spend outside their cells, engaged in 
productive activity (work, education or treatment). 
We Will 
People 
• Refresh the substance misuse and mental health training provided to 
new prison officers and ensure updated training is available for 
existing staff. 
Physical 
Population 
Partnerships 
Procedural 
• Support prisons to establish incentivised substance-free living, 
sharing learning and best practice from the 10 Prisons Project by 
summer 2019. 
• Fully implement the Offender Management in Custody model in all 
prisons by December 2019. 
• Continue to implement the recommendations of Lord Farmer’s review 
to ensure that engagement with families is key to prisons’ approach 
to tackling substance misuse. 
• Create a single, evidence-based Adjudications and Crime in Prison 
Policy Framework and a refreshed Incentives and Earned Privileges 
Policy Framework. 
9 HM Inspectorate of Prisons, (2016), Life in prison: Peer support, 
https://www.justiceinspectorates.gov.uk/hmiprisons/inspections/life-in-prison-peer-support/, p. 4. 
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Building Recovery 
Building 
recovery
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Whole system 
approach 
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Issue 
Prisons aim to prevent reoffending through rehabilitation and overcoming substance 
misuse problems is a key enabler of this. Overcoming addiction is not easy and our 
prisons must have a culture that recognises this and seeks to address the root causes of 
addiction in order to support long-lasting rehabilitation. Backed with processes and 
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procedures which restrict the supply and availability of drugs, and incentive frameworks 
and regimes which reduce the demand for them, prison can provide people with the 
support needed to tackle substance misuse problems, which are often related to the 
crimes that led them to prison. The Offender Management in Custody model will enable 
prison and probation officers to develop positive relationships with prisoners, refer them to 
appropriate services, and achieve the rehabilitative and educational objectives needed to 
tackle demand for drugs, avoid exploitation of this vulnerable group and reduce reoffending. 
Many prisoners have complex needs and have suffered from trauma, with rates of 
substance misuse, mental health problems and poor physical health higher among 
prisoners than among the general population.10 Comorbidity rates are also high, with 
many prisoners who misuse drugs also suffering from mental health issues. Being in 
prison can often exacerbate poor mental health and wellbeing and prisoners can turn to 
drugs (illicit drugs and/or medication not prescribed to them) in an attempt to tackle these 
problems. The misuse of drugs can have tragic consequences, and in recent times we 
have seen an increase in the number of deaths in custody in which substance misuse 
appears to have been a factor. 
Our Work 
Treatment 
More than any other part of our strategy, this is an area in which we work closely with our 
partners. That is why we have worked together to develop the National Partnership 
Agreement (NPA) for Prison Healthcare in England, signed in April 2018 by all of those 
who have a role in the policy, commissioning and delivery of health services in prisons.11 
The partnership includes MoJ and DHSC as well as NHS England, Public Health England 
(PHE) and HMPPS. One of the top priorities outlined in the NPA is reducing the impact of 
substance misuse, addressing the risks and resultant harms of misuse, and ensuring the 
right help is available at the right time. In December 2018, NPA partners published a 
workplan outlining the details of the activities which are being undertaken to deliver its 10 
priorities.12 These priorities, and the activities described in the workplan, will be subject to 
review and updated as the work of the National Partnership for Prison Healthcare in 
England progresses. The Welsh Government and NHS Wales has agreed a set of shared 
priorities with HMPPS for prison health and well-being in Wales, which includes 
developing a standardised clinical pathway for the management of substance misuse 
in prisons in Wales. 
In April 2018, NHS England published a new Service Specification for Integrated 
Substance Misuse Treatment Services in prisons in England. This brings greater focus to 
treatment for users of psychoactive substances, an area which needed refreshing to 
                                               
10 Lord Bradley, (2009), The Bradley Report: Lord Bradley’s review of people with mental health 
problems or learning disabilities in the criminal justice system, 
https://webarchive.nationalarchives.gov.uk/20130105193845/http:/www.dh.gov.uk/prod_consum
_dh/groups/dh_digitalassets/documents/digitalasset/dh_098698.pdf, p. 97. 
11 HM Government & NHS England, (2018), National Partnership Agreement for Prison Healthcare 
in England, https://assets.publishing.service.gov.uk/government/uploads/system/uploads/ 
attachment_data/file/697130/moj-national-health-partnership-2018-2021.pdf 
12 HM Government & NHS England, (2018), National Partnership Agreement for Prison Healthcare 
in England, Workplan 2018-2021, https://assets.publishing.service.gov.uk/government/ 
uploads/system/uploads/attachment_data/file/764884/NPA_Workplan_for_Publication.pdf 
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reflect the changing patterns of drug users. NHS England is also developing a programme 
of work to scope substance misuse interventions that can affect a step change in health 
responses to psychoactive substances. This will consider training for staff, first aid 
interventions and wider recovery activities.  
The new Service Specification also emphasises stronger links to mental health treatment 
so that there is ‘no wrong door’ for prisoners who are seeking help – they will receive 
support from both substance misuse and mental health services if the issues that they 
present require that support. Given the co-morbidity of substance misuse and mental 
health problems, this is a vital step forward and will help more people to get the support 
that they need. 
In July 2018, we announced a joint MoJ/HMPPS, DHSC and NHS England £9 million 
Drug Recovery Prison pilot at HMP Holme House to tackle drugs in prison and help 
prisoners to build their recovery. There we are working hand-in-hand with NHS England 
with a significant portion of the additional investment going towards helping prisoners 
break drug misuse habits. The three-year pilot at HMP Holme House includes new health 
staff, including a specialist psychologist, delivering enhanced substance misuse services 
to ensure prisoners have the support they need. There is also a Connecting Communities 
team helping prisoners to transition from custody to community by aiding family 
engagement and arranging appointments for drug and alcohol treatment, accommodation 
and financial advice. Successful initiatives and lessons learned at HMP Holme House will 
be shared with the rest of the estate and inform best practice. We are also exploring with 
health partners potential opportunities to replicate the Drug Recovery Prison concept 
within the secure estate and on release. 
However, no single model will suit all prisoners and establishments, so we need to make 
sure that each establishment is able to identify the needs of its prisoners and that 
governors work effectively with their health partners to ensure that services are meeting 
the needs of their prison population. To do this, prison governors will need to consider the 
substances that are most prevalent in the prison, the demographic mix of the cohort, the 
needs that they might have, and the range of different interventions that might be required 
– whether that be medication, psycho-social support, the involvement of families and 
peers, or another approach that we know to be effective. The guidance provided 
alongside this strategy will support governors to do this and find ways to improve 
collaborative working. 
The importance of this work is emphasised by the fact that the misuse of drugs can have 
tragic consequences. While we monitor drug-related deaths, historically we have not used 
this category in published statistics. In light of the apparent increase in the number of such 
cases, we are working with the Office for National Statistics to devise and implement a 
recording system that allows the identification of drug-related deaths in prisons. We aim to 
publish the first statistics using this category in July 2019.  
We are also working with the Ministerial Council on Deaths in Custody to reduce the 
number of drug-related deaths. All the strands in this strategy will contribute towards this, 
as will wider work on safety in prisons and support for those with health conditions, 
including mental health. Partnership working is also crucial here, so we are working with 
the Home Office and DHSC to ensure a holistic approach.  
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Prescription and Pharmacy Drugs 
Prescribed medicines are widely used and misused in prisons, presenting considerable 
challenges to safety. In 2015, Her Majesty’s Inspectorate of Prisons’ thematic report on 
changing patterns of drug misuse in prisons found that one in ten prisoners said that they 
had used either opiate substitute medication or other medication not prescribed to them.13 
18% of respondents said they had misused at least one medication, with the most 
commonly used illicit medications painkillers (10%) and medication to assist sleep (10%). 
Misuse of prescription drugs is particularly prevalent in the female estate and can be more 
difficult to detect. Some prisoners request prescribed medication for the psychotropic 
effect of the drug and many will divert their prescribed treatment by trading or selling it to 
others. This risks harmful side effects, interactions and overdoses, as well as contributing 
to the illicit economy and increasing the risk of debt.  
We must reduce the misuse of prescription and pharmacy medication and the diversion of 
prescriptions away from those to whom they are prescribed, while ensuring the 
appropriate range of treatments and interventions for those who need them. To do this, 
we are ensuring that healthcare professionals have appropriate, safe and secure areas to 
practice in and that administration of medicines is orderly to minimise the risk of diversion. 
Prison officers work together with healthcare staff to ensure medication is used 
appropriately and all prisons are recommended to have a Medicines Management 
Committee to oversee this process. 
Continuity of Care 
We must remember that care and our responsibility doesn’t stop when a prisoner leaves 
the prison. The change in circumstances associated with moving from custody to the 
community presents a risk of relapse – in 2017/18, only 32% of offenders in England with 
substance misuse treatment needs were successfully engaged in community-based 
treatment within 21 days of release from prison.14  
This points to the importance of continuity of care and the role that the National Probation 
Service, Community Rehabilitation Companies and General Practitioners play in 
supporting prisoners as they transition back into the community. For prisons in south 
Wales, the Counselling, Assessment, Referral, Advice and Throughcare (CARAT) service 
is provided by Dyfodol, commissioned by HMPPS in Wales and the South Wales Police 
and Crime Commissioner. This provides an integrated service from police custody, to court, 
probation, custody and into the community, providing continuity of care for offenders. 
In August 2018, Public Health England published an audit toolkit and guidance on 
improving continuity of care between custody and the community, with advice for prisons 
and local healthcare providers on how to improve transitions and ensure effective working 
relationships.15 GP practices are required to accept pre-registration by prisoners coming 
                                               
13 HM Inspectorate of Prisons, (2015), Changing patterns of substance misuse in adult prisons and 
service responses, https://www.justiceinspectorates.gov.uk/hmiprisons/wp-
content/uploads/sites/4/2015/12/Substance-misuse-web-2015.pdf, p. 34. 
14 Public Health England, (2018), Public Health Outcomes Framework, 
https://fingertips.phe.org.uk/profile/public-health-outcomes-framework/data#page/0/gid/ 
1000042/pat/6/par/E12000004/ati/102/are/E06000015, indicator 2.16 
15 Public Health England, (2018), Continuity of care for prisoners who need substance misuse 
treatment, https://www.gov.uk/government/publications/continuity-of-care-for-prisoners-who-
need-substance-misuse-treatment 
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to the end of their sentence and once fully implemented, this will support rehabilitation by 
helping to prevent any delays in accessing necessary treatments on release. For 
substance misuse specifically, Single Points of Contacts (SPOCs) for substance misuse 
treatment services in custody will be re-established to improve the sharing of health 
information through the gate. The plan is to relaunch the functional mailboxes for these 
services to encourage secure information sharing between custody and the community. In 
addition, the development of a web-based SPOC database is being explored to facilitate 
improved information sharing between treatment providers in prisons and the community. 
In January 2019, NHS England published their Long Term Plan, which outlined 
commitments to expand Community Service Treatment Requirements and introduce a 
‘RECONNECT’ service to improve continuity of care for prisoners on release from 
custody.16 We welcome this focus on building recovery and we will continue working in 
partnership to ensure that prisoners with substance misuse issues see the benefits of this 
investment. 
We are working to help join up different individuals and organisations to minimise as far as 
possible the risk of people slipping back into drug misuse after working hard to tackle 
addiction while in prison. A key contributor to this is ensuring that everyone leaving prison 
has somewhere stable and secure to live. Since October 2018, prisons and probation 
providers have had a legal ‘duty to refer’ anyone who is homeless or at risk of becoming 
homeless to the Local Authority. The Government has also launched a £100 million 
initiative to reduce and ultimately eliminate rough sleeping across England. Through this 
work, we will invest £6.4 million in a pilot scheme to support prisoners released from HMP 
Bristol, HMP Leeds and HMP Pentonville to secure stable accommodation which will 
promote their rehabilitation. The pilots will test a new partnership approach with prisons, 
probation providers and local authorities working together to plan, secure and sustain 
accommodation for prisoners on their release. We will use the lessons from the pilots to 
inform future provision of accommodation for ex-offenders. 
                                               
16 NHS England, (2019), NHS Long Term Plan, https://www.longtermplan.nhs.uk/online-
version/appendix/health-and-the-justice-system/ 
Prison Drugs Strategy 
23 
 
Our Aims  
To reduce the number of drug-related deaths in custody. 
To increase the proportion of those prisoners who complete treatment who do not return 
within six months, by December 2020. 
To increase the proportion of prisoners with substance misuse treatment needs who are 
successfully engaged in community-based treatment within 21 days of release from prison, 
by December 2020. 
We Will 
People 
• Work with Public Health England to promote their audit toolkit and 
guidance on continuity of care and encourage prisons to reflect on 
their current arrangements and how liaison with community 
healthcare providers and GPs could be improved. 
Physical 
Population 
Partnerships 
Procedural 
• Ensure the safe and secure dispensing of pharmacy and prescription 
medication, including the use of medicine safes where necessary. 
• Publish statistics on the number of drug-related deaths in custody by 
July 2019. 
• Continue to work closely with NHS England, Public Health England, 
the Welsh Government, devolved health bodies, and other partners 
to ensure an effective, joined-up healthcare and treatment offer for 
prisoners. 
• Re-establish Single Points of Contact for substance misuse 
treatment services in custody in England by December 2019. 
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Conclusion and next steps 
This strategy sets the direction for MoJ, HMPPS and key partners to combat drug misuse 
in prisons. Working collaboratively to restrict supply, reduce demand and build recovery 
will ensure that we make a real, positive difference to the safety of our prisons, prison staff 
and prisoners, as well as helping individuals to change their lives.  
We have already begun to implement this strategy and will discuss the strategy with key 
partners from the prison service, law enforcement and health to ensure a consistent 
approach to implementation. We will also continue to develop communication channels 
across MoJ, HMPPS and key partners so that further good practice and learning is shared 
and adopted where beneficial. The guidance that has been compiled alongside this 
strategy provides clear and consistent information for prison governors and staff to 
support their efforts to tackle drugs in their establishments. We will continue to update this 
guidance with new information and examples as these are developed to ensure that 
operational staff have easy access to the best advice. 
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